Thymalin vs. Thymulin Peptide: Benefits, Research, and Differences

Key Takeaways

• Compounds covered: Thymalin, thymulin
• Goal area: Immune function, T-cell maturation, thymic support, aging biology
• Evidence range: Ranges from Russian clinical cohort data (thymalin — 15-year follow-up mortality data from non-blinded, non-randomized cohort analyses that do not meet FDA interventional trial standards and have not been independently replicated) to well-characterized endocrine physiology (thymulin — extensive mechanistic literature) to limited therapeutic intervention data
• Regulatory status: Neither compound is FDA-approved for any indication in the US, and neither is on FDA's 503A or 503B bulk drug substances lists
• Key biomarkers for thymic immune support: CBC with differential (lymphocyte and neutrophil counts), hs-CRP, zinc, IGF-1, comprehensive metabolic panel
• As of April 2026: Neither thymalin nor thymulin is FDA-approved for any indication in the US. Thymalin has a Russian pharmaceutical registration (not recognized by FDA). Neither compound has a lawful US compounding pathway under Section 503A or 503B.
• Bottom line: Thymalin and thymulin are distinct compounds with different structures, origins, and evidence bases — they should not be conflated or equated in research literature, and neither has a lawful US compounding pathway under federal law.

Understanding Thymic Immunity: The Biology

The thymus is a specialized primary lymphoid organ located in the anterior mediastinum, responsible for the development and education of T lymphocytes — the cellular immune system's primary adaptive responders. Immature T cell precursors migrate from bone marrow to the thymus, where they undergo selection and maturation processes that generate the full repertoire of self-tolerant, antigen-specific T cells that constitute adaptive immunity. Without thymic education, T cells cannot function appropriately — they either fail to respond to pathogens or react against self-tissues.

The thymus undergoes progressive involution with age, a process that begins in adolescence and accelerates after 40. By age 60, functional thymic tissue constitutes a fraction of its peak volume. The consequence is a gradual reduction in naive T cell output, contraction of the T cell repertoire, and impaired capacity to mount responses to novel antigens. Hadden and colleagues, writing in the Annals of the New York Academy of Sciences in 1992, reviewed thymic involution in aging and the prospects for correction, framing the decline of thymic function as a central mechanism in immunosenescence.

Two distinct peptide categories interact with this system. The first is thymalin — a polypeptide bioregulator proposed to restore thymic signaling in involuted tissue through epigenetic and transcriptional mechanisms. The second is thymulin — the thymus's own endogenous signaling hormone, a zinc-dependent nonapeptide produced by thymic epithelial cells that directly promotes T cell maturation. Both operate on the same biological system but through different mechanisms and represent different scientific traditions.

Zinc is foundational to understanding thymulin because the hormone is only bioactive in its zinc-bound form. Age-related zinc deficiency — common in elderly populations due to reduced dietary intake and impaired intestinal absorption — directly reduces effective thymulin levels, creating a nutrient-mediated component to immunosenescence that is independent of structural thymic involution.

Thymalin and Thymulin: A Quick Comparison

The following compounds have published evidence relevant to thymic immune function and aging. They are listed for comparison; direct efficacy comparison is not possible because they have been studied in different populations with different endpoints.

• Compound: Thymalin
  Mechanism for immune support: Bovine thymus-derived polypeptide bioregulator; a single in-vitro study (Khavinson 2020) reported activation of haematopoietic stem cell differentiation — proposed as the cellular basis for tissue-specific signaling, pending independent replication.
  Evidence: Russian cohort data including 15-year mortality follow-up in elderly patients and a 266-patient non-randomized analysis; findings have not been replicated in an FDA-standard RCT
  FDA status: Not FDA-approved for any indication; not on FDA's 503A or 503B bulk drug substances lists; no lawful US compounding pathway
  SP availability: Not currently available through Superpower
  Route: Intramuscular injection in Russian clinical protocols
• Compound: Thymulin
  Mechanism for immune support: Endogenous zinc-dependent thymic nonapeptide hormone; promotes T-cell maturation and differentiation; produced by thymic epithelial cells; bioactivity requires zinc binding
  Evidence: Extensive mechanistic and physiological characterization of endogenous thymulin biology. Exogenous administration has been studied in animal models and in gene-therapy-vector approaches in animals. As of April 2026, no completed human clinical trials of exogenous thymulin as a therapeutic have been published.
  FDA status: Not FDA-approved for any indication; not on FDA's 503A or 503B bulk drug substances lists; no established US compounding pathway
  SP availability: Not currently available through Superpower
  Route: Endogenous production; exogenous administration routes under investigation in gene therapy models

Thymalin and Thymulin: Individual Profiles

Thymalin and thymulin represent different scientific traditions and different intervention strategies for thymic immune support. They cannot be compared directly in terms of efficacy because they have different mechanisms, different evidence bases, and have not been tested head-to-head in any published study.

Thymalin

Thymalin is a polypeptide complex derived from bovine thymus gland tissue, developed within the Khavinson bioregulator framework at the St. Petersburg Institute of Bioregulation and Gerontology. It has a Russian pharmaceutical registration (granted by the Ministry of Health of the Russian Federation) for immunomodulatory indications; registration with a foreign regulator is not equivalent to FDA approval, and evidentiary standards differ materially from the FDA's new drug application (NDA) or biologics license application (BLA) pathways. Khavinson and colleagues published a review in Neuroendocrinology Letters in 2002 placing thymalin within the bioregulator framework alongside epithalamin, characterizing both as tissue-specific peptide preparations proposed to support declining organ function in aging. The proposed mechanistic basis for thymalin's immunological activity was examined by Khavinson and colleagues in the Bulletin of Experimental Biology and Medicine in 2020, reporting that thymalin activates differentiation of human haematopoietic stem cells in vitro — providing a proposed cellular mechanism.

The primary human evidence comes from two longitudinal analyses. Khavinson and colleagues, publishing in Neuro Endocrinology Letters in 2003, reported reduced all-cause mortality in a 15-year follow-up of elderly patients who received thymalin and epithalamin compared with a non-randomized control group — a finding from Russian clinical research that has not been independently replicated under FDA clinical trial standards. A separate analysis by Khavinson and Morozov (Uspekhi Gerontologii, 2002) reported approximately 2-fold lower mortality in 266 elderly patients treated with thymalin and epithalamin versus a non-randomized control group — a non-blinded, non-randomized cohort analysis from the Khavinson group; methodology does not meet FDA interventional trial standards and the magnitude of effect has not been independently replicated. Khavinson and colleagues published supporting clinical results in Advances in Gerontology in 2013, reporting clinical outcomes of peptide bioregulators as geroprotectors. A companion paper by Khavinson and colleagues, published in Advances in Gerontology in 2012, reported the experimental-study results that accompanied the clinical-results communication. Anisimov and Khavinson, writing in Biogerontology in 2010, reviewed peptide bioregulation of aging with results and prospects. Khavinson and colleagues' 2002 work in Advances in Gerontology described tissue-specific action of bioregulator peptides in tissue culture of rats at various ages, supporting the organ-selectivity hypothesis.

A related synthetic Khavinson-tradition dipeptide, L-Glu-L-Trp (thymogen), has also been studied; it is not FDA-approved in the US. Anisimov and colleagues, writing in Biogerontology in 2000, reported that the synthetic dipeptide L-Glu-L-Trp (thymogen) slows aging and inhibits spontaneous carcinogenesis in rats. Anisimov and colleagues published a broader review in Voprosy Onkologii in 2009 covering 35 years of research on peptide bioregulators for cancer prevention. [Human longitudinal data — non-randomized cohort studies from the Russian clinical research context; methodological standards differ from FDA Phase 3 RCT requirements]

Thymalin is not FDA-approved for any indication. The FDA does not recognize Russian approval. Thymalin is not on FDA's 503A or 503B bulk drug substances lists, has no USP/NF monograph, and does not have a lawful US compounding pathway under federal law. Not available through Superpower.

Thymulin

Thymulin is an endogenous nonapeptide hormone with the sequence Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, produced exclusively by thymic epithelial cells and released in a zinc-complexed, biologically active form. Its foundational characterization comes from Bach and Dardenne, whose 1989 paper in Medical Oncology and Tumor Pharmacotherapy characterized thymulin as a zinc-dependent hormone. Dardenne and Pleau, writing in Metal-Based Drugs in 1994, reviewed zinc-thymulin interactions and the zinc-binding domain. Folch and colleagues, writing in Biological Research in 2010, provided immunohistochemical evidence of thymulin-containing cells in involuted thymus and peripheral lymphoid organs.

The clinical relevance of thymulin's zinc dependency was established in work by Prasad and colleagues. Writing in the Journal of Clinical Investigation in 1988, Prasad and colleagues documented decreased serum thymulin activity in human zinc deficiency, corrected by zinc supplementation — a finding that connects the common condition of marginal zinc deficiency to impaired adaptive immunity through the thymulin pathway. Saha and colleagues, writing in the International Journal of Immunopharmacology in 1995, showed zinc induces thymulin secretion from human thymic epithelial cells and augments splenocyte responses in vivo. Coto and colleagues, writing in the Proceedings of the National Academy of Sciences in 1992, demonstrated that interleukin-1 regulates secretion of zinc-thymulin by human thymic epithelial cells, integrating thymulin into the cytokine-regulated immune network.

Safieh-Garabedian and colleagues, writing in the Journal of Autoimmunity in 1992, reviewed thymulin's role in immunomodulation, establishing its centrality to T-cell education. Reggiani and colleagues published a comprehensive overview of the thymus-neuroendocrine axis in the Annals of the New York Academy of Sciences in 2009, detailing the physiology, molecular biology, and therapeutic potential of thymulin. Reggiani and colleagues, writing in Current Pharmaceutical Design in 2014, provided a review of the physiology and therapeutic potential of the thymic peptide thymulin, and Reggiani and colleagues, publishing in Neuroimmunomodulation in 2011, documented thymulin-based gene therapy effects on hypothalamic-pituitary-immune axis function in animal models of aging. [Extensive mechanistic and physiological literature; limited human intervention data for exogenous thymulin administration as a therapeutic agent]

Thymulin is not FDA-approved as a therapeutic for any indication. As an endogenous hormone, it is a research target and physiological marker rather than a commercially established drug. Its therapeutic development is at an early preclinical stage.

Regulatory Status at a Glance

As of April 2026, both compounds discussed in this article are not FDA-approved for any indication and do not have a lawful US compounding pathway under federal law.

• Thymalin: Not FDA-approved for any indication; has a Russian pharmaceutical registration for immunomodulatory use (FDA does not recognize foreign approvals); not on FDA's 503A or 503B bulk drug substances lists and has no USP/NF monograph; no lawful US compounding pathway
• Thymulin: Not FDA-approved as a therapeutic for any indication; an endogenous hormone studied for its physiological decline and for gene therapy approaches; not on FDA's 503A or 503B bulk drug substances lists; no established US compounding pathway

For context on the broader regulatory landscape for unapproved peptide compounds, Mendias and Awan reviewed approved and unapproved peptide therapies for musculoskeletal and athletic-performance applications in Sports Medicine in 2026 (PMID 41966639); although thymic peptides were not the focus of that review, the regulatory framing the authors describe for unapproved peptides is instructive.

Considerations When Comparing Thymalin and Thymulin

Direct comparison between thymalin and thymulin is not methodologically straightforward — they have been studied in different populations, using different endpoints, and from different scientific traditions. Thymalin's human data comes from Soviet-era and Russian clinical research with methodological standards that differ from FDA Phase 3 RCT requirements. Thymulin's literature is primarily mechanistic and physiological, with limited human therapeutic intervention data.

Your specific immune concern: Age-related immunosenescence — the gradual contraction of T cell repertoire diversity — and zinc-deficiency-mediated thymulin insufficiency are distinct problems that might favor different approaches. A provider would characterize the immune concern precisely before considering either compound.

Existing health conditions and biomarker profile: Zinc deficiency is the single most important modifiable factor for thymulin bioactivity. Correcting zinc deficiency through dietary or supplementation strategies is a well-evidenced, low-risk intervention with direct thymulin effects — and should precede any discussion of unapproved thymic peptides. Measuring zinc alongside immune markers provides the context for that conversation.

Evidence level comfort: Thymalin has human longitudinal mortality data, albeit from a specific research context. Thymulin's value as a biomarker of immune aging is well-established; its therapeutic use through exogenous administration is at a much earlier stage. A provider will weigh these distinctions.

Regulatory status and access: Neither compound is FDA-approved, and neither is on FDA's 503A or 503B bulk drug substances lists. Neither has a lawful US compounding pathway under federal law as of April 2026.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety data for both thymalin and thymulin as therapeutically administered compounds is limited relative to FDA-reviewed medications. Thymalin's Russian clinical experience over decades provides some safety context but does not constitute the systematic adverse event documentation of an FDA Phase 3 trial. Thymulin's safety as an exogenous therapeutic has been evaluated primarily in animal models.

Contraindications that apply broadly to thymic peptide therapy include:

• Active autoimmune disease — compounds that activate T-cell differentiation carry theoretical concern regarding disease flare in patients with autoimmune conditions; this requires careful provider evaluation
• Active malignancy — immunomodulatory peptides have not been systematically studied in oncology patients outside specific research contexts; use requires oncology provider input
• Pregnancy and breastfeeding — no reproductive safety data exists for either compound
• Known hypersensitivity to bovine-derived proteins — thymalin is derived from bovine thymus; allergy evaluation is relevant before use
• Organ transplantation patients on immunosuppressive therapy — immune stimulation could interact with maintenance immunosuppression

For compound-specific safety profiles, see individual compound pages as the peptides cluster expands.

What to Test Before Starting Peptides for Thymic Immune Support

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes a measurable starting point for immune function. For thymulin specifically, testing zinc levels is the critical first step — because zinc deficiency is the most directly modifiable contributor to reduced thymulin bioactivity and is addressable without any prescription compound.

• CBC with differential (including lymphocyte count): Measures white blood cell populations including the T and B lymphocyte categories. Why it matters: the absolute white blood cell count and lymphocyte percentage provide a baseline characterization of immune cell abundance before any thymic peptide intervention.
• hs-CRP: Measures systemic inflammatory burden. Why it matters for thymic immune support: chronic low-grade inflammation is associated with accelerated immune aging and may reflect the same processes that thymic peptides are proposed to address. High-sensitivity CRP provides the inflammatory baseline that contextualizes immune function data.
• Zinc (serum or plasma zinc): Directly relevant to thymulin bioactivity. Why it matters: zinc deficiency impairs thymulin activity, reducing T-cell maturation independently of structural thymic involution. Prasad and colleagues documented that correcting zinc deficiency restores thymulin activity in humans. Zinc status should be established before any thymulin-related discussion.
• IGF-1: The primary downstream marker of growth hormone axis activity. Why it matters in the thymic context: IGF-1 supports thymic function and immune cell proliferation; age-related decline in IGF-1 is associated with accelerated thymic involution. Measuring IGF-1 levels provides the hormonal-immune axis context relevant to thymalin and thymulin discussions.
• Comprehensive metabolic panel (ALT, AST, eGFR): Liver and kidney function markers that establish safety context for any injectable compound protocol and identify organ function concerns that would affect compound processing.
• Vitamin D (25-hydroxy): Vitamin D has modulatory roles in adaptive immunity and thymic function. Deficiency is common and independently impairs immune responses. Testing vitamin D alongside zinc addresses the two most common nutrient-related contributors to impaired thymic immunity.

CBC with differential, hs-CRP, zinc, and IGF-1 together provide the immune health baseline relevant to thymalin and thymulin discussions. Testing immune system biomarkers before starting any protocol creates the reference data needed to interpret subsequent immune changes.

Regulatory and Access Context for Compounded Thymic Peptides

Thymalin and thymulin do not have a lawful US compounding pathway under Section 503A or 503B as of April 2026 — neither is on FDA's bulks lists, and neither has a USP/NF monograph. A licensed US prescriber cannot generally source these compounds through an FDA-compliant compounding pharmacy. Individuals who encounter these compounds in a clinical conversation should ask their provider where the product originates and whether its sourcing is consistent with federal law.

Some thymalin and thymulin products are sold by research-chemical suppliers with "Research Use Only" (RUO) labeling. RUO products are intended for laboratory research, are not manufactured to pharmaceutical quality standards, and are not labeled or approved for human use. Using an RUO-labeled peptide in a human is outside FDA's intended-use framework and carries material regulatory and safety risk.

Before any conversation about unapproved thymic peptides, a provider evaluation should characterize the immune concern precisely and rule out modifiable contributors (zinc deficiency, vitamin D deficiency, ongoing infections). Thymalin in the Russian clinical context was administered by intramuscular injection; no standardized US clinical protocol exists. Products sold through online vendors without a licensed pharmacy and prescriber chain cannot be verified for identity, purity, or dose accuracy, and individuals should not rely on internet-sourced protocols.

Understanding Your Baseline

Thymalin and thymulin both target the same fundamental biological system — the decline of thymic function with age — but through different mechanisms and with different evidence bases. The decision about which, if either, is relevant for a specific individual cannot be made without knowing where that individual's immune function, zinc status, and hormonal context currently stand. A zinc deficiency that is directly impairing thymulin bioactivity is addressable without any prescription peptide. A provider evaluation grounded in objective baseline data is the appropriate starting point.

That principle is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to addressing a nutrient deficiency, discussing a compounded thymic peptide, or pursuing a different strategy entirely, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

Thymalin is not approved by the FDA for any indication. It has a Russian pharmaceutical registration for immunomodulatory indications; the FDA does not recognize foreign approvals. Thymalin is not on FDA's 503A or 503B bulk drug substances lists, has no USP/NF monograph, and does not have a lawful US compounding pathway under federal law. Its use for immune support or longevity has not been evaluated or endorsed by the FDA, and the safety and efficacy for US indications have not been established through adequate and well-controlled clinical trials. Superpower does not currently offer thymalin. Always consult a licensed healthcare provider before initiating any peptide protocol.

Precautions and theoretical concerns: thymalin is derived from bovine thymus tissue — individuals with known allergies to bovine-derived products should discuss this with a provider before use. Immunomodulatory compounds carry theoretical concern for exacerbation in patients with autoimmune disease, active malignancy, or those on immunosuppressive therapy post-transplantation; these populations require specific provider evaluation. No reproductive or developmental safety data exists. Systematic adverse event data meeting FDA standards does not exist for US populations.

Thymulin as a therapeutic compound is not FDA-approved for any indication. It is not on FDA's 503A or 503B bulk drug substances lists and has no established US compounding pathway. Thymulin's therapeutic development is at an early preclinical and early research stage. Its use through exogenous administration has not been evaluated in completed human clinical trials. Thymulin is not prescribed, compounded, or dispensed through Superpower. This section is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

Full FDA-approved prescribing information for any prescription compound at dailymed.nlm.nih.gov.